Connect with us

Stock Value

Biotech Stocks and Selecting a Broker

Avatar

Published

on

biotech stock value

Could biotechnology stocks triple in a year? Read on to find out the answer to this question and learn the Top 3 Biotech stocks as recommended by a finance degree holder from University of Samoa.

Selecting a Broker and Biotech Stocks

Dear Mr. Berko:

I am 32 and recently got a doctorate in French history. After 14 years of attending classes, I will apply for my first ever job at UCLA, which would pay me about $55,000 a year. But first I will take nine months to go on a needed vacation and live with three friends in Marseille. I have about $173,000 in student debt but managed to save $21,000 while borrowing. While I’m in France, I’d like to invest $10,000 in biotechnology stocks because my sister, a high school science teacher, says biotech stocks could triple in a year. I want to make money fast. Do you have any recommendations for low-priced biotech stocks?

I also need to find a brokerage firm. I’ve searched social media — because they have interactive, personally shared, honest, community-based, non-commercial information — for the best brokerage firm. I got five recommendations — namely, TD Ameritrade, Charles Schwab, E-Trade, Merrill Edge and Fidelity. Please advise and tell me which is the best firm to invest with.

— PD, Portland, Ore.

Dear PD:

Something’s terribly wrong here. How can a system allow you to accumulate that much debt? And how can you justify owing that much money (unless you don’t intend to pay it back) for a job that pays $55,000 a year?

Meanwhile, never ever use social media for important financial information. In the past several years, social media have morphed into a public display for personal perversions and become a marinade for the human brain and a cause celebre that revolutionizes rather than evolutionizes changes in the landscape of our American culture.

It doesn’t make a tinker’s dam’s worth of difference which brokerage you use, because there’s not an iota of difference among those five firms. They execute trades equally as well. They’re all adequately capitalized. All have good investment tools, provide competent stock research data and issue easily readable monthly statements. Their trading costs are nearly identical. Fourteen years of college may have taught you what to think, but you seem to have failed to learn a more important skill — how to think.

You should pick the broker, not the brokerage, because the broker is the person whose knowledge, wisdom and experience will help you select the best investments for your goals. For example, Merrill is a darn fine firm. However, it, like all others, has its share of incompetents with room temperature IQs, and if you stand close enough to them, sometimes you can hear the ocean roaring.

Because I know little about biotech stocks, I called Swami Sammy Sosa, who has always been a font of information for me. Swami Sammy was Bernie Madoff’s personal golf caddie and claims to have a doctorate in finance from the University of Samoa.

His biotech recommendations are as follows:

Sangamo Therapeutics (SGMO-$14.75) is into groundbreaking genomic therapies using proprietary platforms in genome editing, gene therapy, gene regulation and cell therapy. Swami Sammy and Piper Jaffray think this could be a $30 stock by 2019.

ImmunoGen (IMGN-$5.50) is engaged in the discovery of monoclonal antibody-based anti-cancer therapeutics using its proprietary antibody-drug conjugate technology, which binds to a target found on tumor cells. Swami Sammy and RBC Capital Markets think this could double in the next 19 months.

Finally, Neos Therapeutics (NEOS-$9.50) is a favorite of Cantor Fitzgerald and Swami Sammy’s. It develops, manufactures and commercializes products for the treatment of attention deficit hyperactivity disorder, using various delivery technologies that improve the efficacy of ADHD drugs. This could be a $17 stock in 18 months. You could invest $3,300 in each, and if you used Schwab, the total commission costs would be $15.

Be mindful that these issues are horribly speculative and may decline in price before they rise in price, if they rise at all. I think you’d be nuts to speculate with these issues, even though each is prominent in the growth portfolios of BlackRock, Goldman Sachs, State Street, Vanguard, Fidelity, Morgan Stanley and others.

Biotechnology is a volatile sector, and fast money will be made and lost — mostly lost. But you’ve nothing to lose, because that’s not your money.

Please address your financial questions to Malcolm Berko, P.O. Box 8303, Largo, FL 33775, or email him at [email protected] To find out more about Malcolm Berko and read features by other Creators Syndicate writers and cartoonists, visit the Creators Syndicate website at www.creators.com.
COPYRIGHT 2017 CREATORS.COM

Continue Reading
1 Comment

1 Comment

  1. Pingback: Making Money on Margin | The Capitalist - Grow Financial Wings

Leave a Reply

Your email address will not be published. Required fields are marked *

Stock Value

Making Money on Margin

Avatar

Published

on

Making Money On Margin

How do you make money on margin? How does making money on margin work? Read on to find out the answers from Mr. Malcolm Berko.

Making Money on Margin

 

Dear Mr. Berko:

I got a $10,000 bonus from my employer in January and put it with a broker in early February. He has made four trades, including a biotech stock with a funny name I’ve never heard of.

My account is now worth $12,200. He said if he had my account on margin, then he could have made twice as much money. Is that true? I asked how it works, and he said I won’t have to put up more money but I just have to sign a broker’s form and I can buy twice as much stock immediately. Because he doesn’t explain things well, and I don’t want to offend him, could you please explain how margin works? And is it true that I could have made twice as much money as he claims?

Also, I’d like to buy stock in the fantastic Chinese market. Do you think Chinese stocks will move way up? What Chinese stocks would you recommend?

— LD:, Portland, Ore.

Dear LD:

That broker’s right on the money! If you had signed his margin agreement upon opening the account and followed his advice, you’d have made twice as much money. That margin agreement would give you an extra $10,000 credit so you could buy $20,000 worth of stock. The flip side of that agreement is that you could also lose twice as much.

Here’s a very simple explanation of how it works. Margin accounts, offered by most brokers, enable clients to borrow money to purchase stocks or bonds. Assume you wish to buy 100 shares of the fictional company LSMFT (LSMFT-$100), which would cost you $10,000. You can write the broker a check for $10,000 and own LSMFT free and clear. Or you can sign a margin agreement and buy 100 shares of LSMFT for $10,000, putting down 50 percent of the price ($5,000) and borrowing the remaining $5,000 from your broker. The broker charges interest (today’s rate of 8 percent is turnpike thievery because the collateral is good as gold) on the borrowed $5,000 and he holds your 100 shares of LSMFT for collateral. If the brokerage charges 8 percent simple interest, then $33.33 will be deducted from your account each month. And if 10 months later you sell LSMFT at $110, you’ll have a credit in your account of $11,000, from which you repay the broker the borrowed $5,000. Now you have $6,000 remaining and a gross profit of ($6,000 less $5,000) $1,000. So, after subtracting buying and selling commissions of $150 and 10 months of interest of $33.33 from the $1,000 gross profit you have a net profit of $516.67.

The important thing investors must understand about margin is that it’s a double-edged sword. If you had invested $10,000 in cash, your 10-month return would’ve been 5.16 percent. But you leveraged LSMFT with just $5,000 so your 10-month return is 10.32 percent. When stocks rise in value, your gains are amplified and that’s wonderful. However, in a down market, margin really hurts because the borrowed money exposes you to higher risks. Now, if you can get this in your head, you’ll have it in a nutshell.

The extreme use of leverage is one of the reasons banks like Lehman, Bear Stearns, Merrill, JPMorgan, etc., collectively lost hundreds of billions of dollars nine years ago. Goldman, Citigroup, Bank of America, etc., traded bonds using 1 percent margin, investing only $1,000 for every $100,000 of market value. If the bonds fall 5 percent or $5,000 (many did and more), the $1,000 is wiped out and they’re $4,000 on the wrong side of the eight ball. Multiply this number by billions (remember those subprime mortgages) and you may understand how the great financial crisis occurred.

Individual Chinese stocks scare the bejabbers out of me. I don’t trust China’s banking/financial system or its corporate and government executives. Corporate income statements are bloated, balance sheets are fudged, and I can’t read Pinyin so Chinese corporate reports are Greek to me. But the China market can be hot and I’d own the iShares MSCI China ETF (MCHI-$69) — that’s a Chinese imitation of the S&P 500 Index. MCHI was plus 12.5 percent last year.

Please address your financial questions to Malcolm Berko, P.O. Box 8303, Largo, FL 33775, or email him at [email protected] To find out more about Malcolm Berko and read features by other Creators Syndicate writers and cartoonists, visit the Creators Syndicate website at www.creators.com.
COPYRIGHT 2018 CREATORS.COM

Continue Reading

Stock Value

New Look At Newell Brands

Avatar

Published

on

Newell Brands

Coca-Cola, Dymo, Elmer’s, Contigo, Rubbermaid, Coleman, Oster, Sharpie, Papermate, Sunbeam are just some of the brands which comprise Newell Brands. Newell products are in almost every consumer’s home, office, factory floor, restaurant, supermarket, school and in numerous other venues. Does this mean that Newell brands stock is a good buy? Read on to find out from Mr. Berko.

New Look at Newell

Dear Mr. Berko:

What happened to Newell? I bought 500 shares at $43 in September of 2017. My broker tells me to sell the stock and take a loss and wants me to put the proceeds in American Funds New Perspective. Your advice would be appreciated.

— JM, Moline, Ill.

Dear JM:

New Perspective (ANWPX) is a good fund with a good record and a sweet commission would be paid to your broker.

New Look At Newell Brands

It’s important to know that Newell Brands (NWL-$27) is a $14.7 billion company, and global marketer of consumer and commercial products in more than 200 countries. And most of its brands have high recognition value like Coca-Cola, Microsoft and Kleenex. So, it’s important to know NWL sells Paper Mate, Sharpie, Dymo, Parker, Elmer’s, Coleman, Jostens, Rawlings, Irwin, Lenox, Oster, First Alert, Sunbeam, Mr. Coffee, Rubbermaid Brands, Graco, Baby Jogger, Food Saver, Yankee Candle, Crock-Pot, etc. And, there’s a NWL product in almost every consumer’s home, office, factory floor, restaurant, supermarket, school and innumerous other venues.

Since June of 2017, NWL shares slumped nearly 50 percent from $55 to the current $27 price. NWL’s $15 billion acquisition of Jarden doubled 2016 revenues and earnings grew by 30 percent to $1.25 a share. And in 2017, revenues continued to improve by nearly 12 percent and earnings are expected to come in at an attractive $2.75 a share. These good numbers are the result of an impressive doubling of net profit margins, an improving e-commerce business, brand-enhancing investments, strong distribution networks and employee/management efficiencies.

In 2017, management really hunkered down and NWL benefited handsomely from the Jarden merger (synergies were more positive than management had hoped) and significant cost reductions in raw materials, manufacturing and shipping were reflected in the numbers. However, in the third quarter of 2017, NWL’s revenues slipped nearly 8 percent due to weaker-than-expected back-to-school sales, a difficult consumer market, weather conditions such as a devastating hurricane season and a shift in its hugely diversified portfolio. Resultantly, 2017 earnings of $3.00 a share and revenues of $15 billion were much lower than the Street’s estimate. Numbers for 2017 were dramatically better than all previous years, and still NWL shares plunged from $55 to a low of $25 in late January of 2018.

So, along came the spoilers (like tort lawyers trolling for business). And activist investors in the name of Starboard Value LP are aligning themselves with three former executives of Jarden who are critical of how NWL is running its sprawling menagerie of products. They believe they can do a much better job. Hah! So, now we have a proxy fight as the three former Jarden executives plus Starboard Value (together they own 5 percent of NWL shares) have delivered a letter to NWL’s CEO confirming that they have nominated a full slate of director candidates. And in an immediate response, NWL’s management announced that it was planning to offload brands that failed to meet revenue and profit objectives while closing half its factories to further improve net profit margins. NWL management intends to focus on its core consumer divisions and offloading most everything else won’t add to NWL’s already impressive net profit margins (they may reach 19 percent in three years). And current management believes earnings could come between $4.60 and $4.75 by 2021. Considering those numbers, NWL must be an attractive buy.

I think that the Starboard and Jarden people are wrongheaded and may be defeated. Current management has done a yeoman’s job running NWL, and I don’t see any need for a new board or a change in the executive suite. NWL’s management has produced some excellent numbers and I’d be proud to buy another 500 shares at the current bargain price of $27 to $28. So, considering NWL’s $1 billion share buyback program, a current 88-cent dividend yielding 3.2 percent and a current share price allowing you to own the stock at less than its $30 book value, NWL is a solid buy with a price objective of $65-$70 in the coming three years.

Please address your financial questions to Malcolm Berko, P.O. Box 8303, Largo, FL 33775, or email him at [email protected] To find out more about Malcolm Berko and read features by other Creators Syndicate writers and cartoonists, visit the Creators Syndicate website at www.creators.com.
COPYRIGHT 2018 CREATORS.COM

Continue Reading

Franchises

What Is The State of MasterCard and Consumer Debt During Trump Era

Avatar

Published

on

MasterCard Donald Trump Consumer Debts

Previously known as Interbank Card Association, MasterCard is a group of banks. With Trump’s economic policies and infrastructure spending, how will MasterCard’s stock value fare? Read on to find out from Mr. Malcolm Berko.

MasterCard and Consumer Debt

Dear Mr. Berko:

My brother, who does well in the stock market, told me to buy 100 shares of MasterCard.

He thinks that President Donald Trump’s economic policies and infrastructure spending will grow corporate earnings and give more people jobs and many people higher-paying jobs. He says that these people will spend their money rather than save it. We both believe that the American consumer is born to spend. Please advise. — JA, Indianapolis

Dear JA:

I think your brother is right as light!

Way back in 1966, before marijuana became legal in the Western states, a group of banks formed the InterBank Card Association. And in 1968, when the movie “Planet of the Apes” was released, this association changed its name to MasterCard. In 2006, Goldman Sachs, Citigroup and HSBC took MasterCard (MA-$178) public at $39 a share. And in December 2014, just before Russia annexed Crimea, MA had a 10-for-1 split.

Back in 2007, a stockbroker with whom I occasionally exchange ideas told me to buy MA, which was trading at $46 a share. I wasn’t comfortable with his analysis. I was convinced that consumers had maxed out their personal debt (credit cards, small-loan companies, cars, student loans), because in 2007, they owed a record $10.6 trillion. And that year, the gross domestic product was $14.4 trillion. Those were staggering numbers, and I couldn’t imagine that consumer debt would stagger higher. Well, it did stagger higher. Ten years later, consumer debt had risen to $13.8 trillion, a $3.2 trillion increase, while the GDP had risen to $19 trillion, an increase of $4.6 trillion. I figured that the fit had to hit the shan sooner or later. That 30 percent increase in consumer debt between 2007 and 2017, without an equal increase in consumer income, gave me agita.

I should have bought the darn stock! During the past 10 years, MA’s revenues have grown by 350 percent. Cash flow has increased by 550 percent. Share earnings have boomed by 625 percent. And the dividend, though it’s still cheeseparing, has grown from a nickel to a dollar a share. MA is a global leader in electronic payments and has become the processor, franchisor and adviser to over 25,000 financial institutions in support of their credit, debit and other payment plans. Today MA licenses or franchises its credit card brands (MasterCard, Maestro, Cirrus) to customers all over the planet, with the exception of North Korea. I’m told that Visa (V-$124.71) has a better chance of success in North Korea than MA.

This year, with the help of 12,000 mostly happy employees, MasterCard expects to increase revenues from $12.2 billion to $13.9 billion. That certainly ain’t chopped liver. And with impressive net profit margins of 38.1 percent, management expects to report earnings in 2018 of $5.08 a share (up from $4.45 in 2017), with an increase in its miserly dividend to $1.10.

Too many American consumers are drunk on debt. And as long as they can make monthly payments, it appears that American consumers are still willing to take on more debt. Americans would own kangaroos as pets if they could be bought for $100 down and $50 a month. As employment continues to improve, as the economy continues to pick up steam, as corporate billions come in from overseas, as corporate America continues to improve earnings and grow dividends and as Trump’s economic initiatives gain traction, consumers’ borrowing appetite will push MA’s revenues, earnings and dividends nicely higher during the coming four years. By 2021, MA’s revenues could improve by 40 percent, to $18.5 billion. Earnings could improve by 43 percent, to $7.10 a share. And the dividend could run up 25 percent, to $1.27. And best of all, MA’s net profit margins will probably improve to 40 percent.

However, since December 2015 — when MA was trading in only the mid-$80s — insiders, officers and directors have been selling the stock as the shares have been running up. I wonder why, because Credit Suisse, Argus Research, Market Edge, Zacks, KeyBank, Piper Jaffray, Morgan Stanley and others have “buy” rankings on MA.

Please address your financial questions to Malcolm Berko, P.O. Box 8303, Largo, FL 33775, or email him at [email protected] To find out more about Malcolm Berko and read features by other Creators Syndicate writers and cartoonists, visit the Creators Syndicate website at www.creators.com.
COPYRIGHT 2018 CREATORS.COM

Continue Reading

Trending

Copyright © 2019 The Capitalist. his copyrighted material may not be republished without express permission. The information presented here is for general educational purposes only. MATERIAL CONNECTION DISCLOSURE: You should assume that this website has an affiliate relationship and/or another material connection to the persons or businesses mentioned in or linked to from this page and may receive commissions from purchases you make on subsequent web sites. You should not rely solely on information contained in this email to evaluate the product or service being endorsed. Always exercise due diligence before purchasing any product or service. This website contains advertisements.